BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 122 filers reported holding BRIDGEBIO PHARMA INC in Q2 2020. The put-call ratio across all filers is 0.03 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,595,841 | +3.7% | 150,921 | 0.0% | 0.10% | +7.4% |
| Q1 2023 | $2,502,270 | -78.3% | 150,921 | -20.0% | 0.10% | -74.6% |
| Q2 2021 | $11,507,000 | +150.0% | 188,767 | +152.7% | 0.37% | +136.7% |
| Q1 2021 | $4,602,000 | +259.8% | 74,714 | +90.5% | 0.16% | +222.4% |
| Q2 2020 | $1,279,000 | +12.4% | 39,228 | 0.0% | 0.05% | -3.9% |
| Q1 2020 | $1,138,000 | -17.2% | 39,228 | 0.0% | 0.05% | -1.9% |
| Q4 2019 | $1,375,000 | – | 39,228 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |